Abfero Pharmaceuticals Announces Initiation of Phase 1 Study for Lead Iron Chelator
UF startup AbFero Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO).